Sugi Predict

Sugi Predict / Compounds / SCHEMBL16636889

SCHEMBL16636889

SCHEMBL16636889

N#Cc1cnc2cc(Cl)c(-c3ccc(Cl)cc3)cc2c1O

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 6/20 0.40
▸ EGFR P00533 3/20 0.39
▸ ERBB2 P04626 3/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ RXFP1 Q9HBX9 1/20 0.39
▸ CNR1 P21554 7/20 0.39
▸ CNR2 P34972 6/20 0.39
▸ ABL1 P00519 1/20 0.38
▸ BCR P11274 1/20 0.38
▸ LRRK2 Q5S007 1/20 0.38
▸ MAP2K1 Q02750 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16647208 0.86 SRC (0.42) SRCKDM4EALDH1A1LMNAPOLB
SCHEMBL21891663 0.74 STK4 (0.45) SRCEGFRERBB2CNR1CNR2
SCHEMBL29765779 0.73 ERBB2 (0.45) EGFRERBB2CNR1CNR2LRRK2
SCHEMBL16636768 0.73 ERBB2 (0.45) EGFRERBB2CNR1CNR2LRRK2
SCHEMBL16647101 0.72 RAF1 (0.36) —
SCHEMBL16637620 0.72 TLR8 (0.48) EGFR
SCHEMBL6642503 0.71 EGFR (0.40) SRCEGFRERBB2ALDH1A1ABL1
SCHEMBL30083634 0.71 EGFR (0.40) SRCEGFRERBB2ALDH1A1ABL1
SCHEMBL2975176 0.71 VCAM1 (0.41) EGFRERBB2KDM4EALDH1A1LMNA
SCHEMBL16543993 0.70 EGFR (0.36) SRCEGFRERBB2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2025-02-25 — — US disclosed
US-20240352028-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2024-10-24 — — US disclosed
US-20240043441-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2024-02-08 — — US disclosed
US-11878985-B2 Substituted quinazolines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2024-01-23 — — US disclosed
US-20230303586-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-09-28 — — US disclosed
US-20230212183-A9 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-07-06 — — US disclosed
US-20230212183-A9 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-07-06 — — US disclosed
US-20230212183-A9 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-07-06 — — US disclosed
US-20220242875-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2022-08-04 — — US disclosed
US-20210188869-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2021-06-24 — — US disclosed
US-20160166571-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC 2016-06-16 — — US disclosed
US-20160166571-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC 2016-06-16 — — US disclosed
US-20160166571-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC 2016-06-16 — — US disclosed
WO-2016044772-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC (US) 2016-03-24 — — WO disclosed
WO-2016044772-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC (US) 2016-03-24 — — WO disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
WO-2015054572-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2015-04-16 — — WO disclosed
WO-2015054572-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2015-04-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210188869-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS SRC 333/4885EGFR 180/4885ERBB2 295/4885
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C KRAS, NRAS, HRAS SRC 296/4885EGFR 235/4885ERBB2 285/4885
US-11878985-B2 Substituted quinazolines as inhibitors of KRAS G12C KRAS, NRAS, HRAS SRC 383/4885EGFR 262/4885ERBB2 227/4885
US-20240352028-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS SRC 383/4885EGFR 262/4885ERBB2 227/4885
US-20150239900-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS SRC 333/4885EGFR 180/4885ERBB2 295/4885
US-20230212183-A9 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS SRC 333/4885EGFR 180/4885ERBB2 295/4885
US-20240043441-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS SRC 333/4885EGFR 180/4885ERBB2 295/4885
US-20230303586-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS SRC 333/4885EGFR 180/4885ERBB2 295/4885
US-20220242875-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS SRC 333/4885EGFR 180/4885ERBB2 295/4885
US-20160166571-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER KRAS, TP53, HRAS SRC 484/4885EGFR 16/4885ERBB2 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.